Beam Therapeutics (BEAM) Treasury Shares (2019)

Beam Therapeutics (BEAM) has reported Treasury Shares for 8 consecutive years, with $3.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Treasury Shares rose 8.85% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $3.3 million (up 8.85% YoY), while the FY2025 annual figure was $2.5 million, down 1.28% from the prior year.
• Treasury Shares rose to $3.3 million in Q1 2026 per BEAM's latest filing, from $2.5 million in the prior quarter.
• Across five years, Treasury Shares topped out at $3.4 million in Q1 2024 and bottomed at $1.5 million in Q1 2022.
• Historically, Treasury Shares has averaged $2.5 million across 5 years, with a median of $2.6 million in 2024.
• Annual changes were most pronounced in 2023 — Treasury Shares soared 72.92% — and 2025, when it decreased 14.09%.
• Beam Therapeutics' Treasury Shares stood at $1.7 million in 2022, then jumped by 72.92% to $2.9 million in 2023, then slipped by 11.97% to $2.6 million in 2024, then decreased by 1.28% to $2.5 million in 2025, then soared by 31.4% to $3.3 million in 2026.
• Business Quant data shows BEAM's Treasury Shares at $3.3 million in Q1 2026, $2.5 million in Q4 2025, and $2.8 million in Q3 2025.